New CCO at crisis-hit Lundbeck: "2022 will be a growth year for Lundbeck in all regions"

Jacob Tolstrup will be responsible for renewing sales growth at Lundbeck, having made his way through the ranks.
Jacob Tolstrup, executive vice president and chief commercial officer of commercial operations at Lundbeck | Photo: PR / Lundbeck
Jacob Tolstrup, executive vice president and chief commercial officer of commercial operations at Lundbeck | Photo: PR / Lundbeck
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen

The pipeline has failed, sales of migraine drug Vypeti, which cost billions to acquire, have failed, and so, it seems, has the firm’s ability to make money. Still, the pharmaceutical company’s new CCO, Jacob Tolstrup, is optimistic on Lundbeck’s behalf.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading